Application of Capture-recapture in the Assessment for the Incidence of Adverse Drug Reactions

Abstract

Abstract: Objective To discuss the application of capture-recapture (CR) method in the assessment for the incidence of ADR, and get a more accurate monitoring of the incidence of ADR, in order to provide thought and references for the promotion of ADR monitoring in China.Methods Using the mathematical statistics method to review the principle, and application condition of CR method, and through the case-analysis,it is revealed the role of CR method in the incidence of ADR estimation and some problems about CR method.Results & ConclusionCR method is appropriate for many big databases which can monitor different incidence of ADR.It is the effective method that can estimate the total incidence of ADR and make sure of the incidence of adverse reactions, which is worthy of applying in the research of ADR monitoring.

Key words: capture-recapture method, adverse drug reaction, incidence of adverse reaction

CLC Number:

HAN Fei, WANG Guo-hua, LIU Hui-lan, LI Xiao-li, LI Bing, LIU Jun, WANG Zhong, LU Shu, JING Zhi-wei. Application of Capture-recapture in the Assessment for the Incidence of Adverse Drug Reactions[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 102-104.

References

[1] Manasse H R Jr.Medication use in an imperfect world:drug misadventuring as an issue of public policy, part 1[J]. Am J Hosp Pharmacology, 1989, 46(5):929-944.
[2] 王建刚.自发呈报系统不良反应发生率的内涵及估计[J].药物流行病学杂志, 1996, 5(3):174-178.
[3] Seeger J D, Schumock G T, Kong S X. Estimating the rate of adverse drug reactions with capture-recapture analysis[J].American Journal of Health-System Pharmacy, 1996, 5(3):178-181.
[4] McCarty D J, Tull E S, MoyC S, et al.Ascertainment corrected rates:applications of capture-recapture methods[J]. Int J Epidemiology, 1993, 22(3):559-565.
[5] International Working Group for Disease Monitoring and Forecasting. Capture re-capture and multi-record system estimationⅠ: history and theoretical development[J]. Am J Epidemiology, 1995, 142(10):1047-1058.
[6] Wittes J T, Sidel V W. A generalization of the simple capture-recapture model with applications to epidemiological research[J]. J Chronic Dis,1 968, 21(5):287-301.
[7] Neugebauer R.Application of a capture-recapture method(the Bernoulli census)to historical epidemiology[J]. Am J Epidemiology, 1984, 120(4):626-634.
[8] Laporte R E, Tull E S, McCarty D J.Monitoring the incidence of myocardial infarction:applications of capture-mark-recapture technology[J]. Int J Epidemiology, 1992, 21(2):258-262.
[9] Hook E B, Regal R R.Capture-recapture methods [J]. Lancet, 1992, 339(8795):742.
[10] 李宁,韩瑞婷,王宗耀,等.基于真实世界的中药注射剂疗效评价的研究概述[J].中国中医药现代远程教育, 2016, 19(14):141-142.
[11] 王玲.基于医院信息系统开展药品不良反应监测研究[J].中国药物警戒, 2015, 12(4):229-231,240.
[12] Knowles R L, Smith A, Lynn R, et al. Using multiple sources to improve and measure case ascertainment in surveillance studies: 20 years of the British Paediatric Surveillance Unit[J]. Journal of Public Health, 2006, 2(28):157-165 .
[13] D Böhning,C Viwatwongkasem.Estimating the number of drug users in Bangkok 2001:a capture-recapture approach using repeated entries in one list[J]. European Journal of Epidemiology, 2004, 12(19):1075-1083 .
[14] Stephanie Lugardon, Karine Desboeuf,Pierre Fernet. Using a capture-recapture method to assess the frequency of ADR[J]. British Journal of Pharmacology Clini-cal,2006,2(62):225-231.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.